Navigation Links
Quintiles Consulting Business Expands
Date:4/22/2008

New Practice Leaders Appointed

RESEARCH TRIANGLE PARK, N.C., April 22 /PRNewswire/ -- Quintiles Transnational Corp. today announced the appointment of three new practice leaders and a business development head as part of its expanding Quintiles Consulting business, which provides pharmaceutical, biotech and medical device companies with strategic guidance to maximize potential and minimize risk from early discovery through commercialization.

Quintiles Consulting is expanding its current services and building a premier global consulting organization to provide strategic, operational and technical advice to pharmaceutical, biotechnology and medical device companies. The organization will focus on market leading issues and address client needs in three practice areas: Product Development and Commercialization, Regulatory and Quality, and Market Access.

The new leadership team members are:

John Doyle, Dr.P.H., M.P.H., Practice Leader, Market Access, U.S. - Doyle leads the U.S. Market Access practice, focusing on market access strategy, health economic assessments, outcomes research, and pricing and reimbursement strategy and support. Doyle will work collaboratively with Dr. Jacco Keja of the Netherlands-based Market Access practice to build the business globally, as well as expand and deepen the group's service offerings.

Doyle joins Quintiles from Analytica International, a health economics and market access consulting firm he co-founded and led as President. Prior to that, Doyle directed the Oncology and Immunology Economics Research Group at Bristol-Myers Squibb. Since 1993, Doyle has authored more than 50 original research articles, in a variety of therapeutic areas, with a special focus in cardiology, oncology and ophthalmology. He has consulted with global pharmaceutical and biotech firms on strategic concerns regarding product development, pricing, reimbursement, market valuation and other commercialization issues.

Adrian K. McKemey, Ph.D., Practice Leader, Product Development and Commercialization, U.S. - McKemey leads Quintiles Consulting's Product Development and Commercialization practice, focusing on business transformation, portfolio management, risk partnering, scenario planning and outsourcing strategies.

McKemey was most recently a Principal with the Boston Consulting Group (BCG), working in the Health Care practice and the BCG Strategy Institute. Since 2000, he has helped large pharmaceutical clients optimize product research and development and commercialization through setting strategic direction, developing science policy, reengineering business processes and managing organizational change. Prior to BCG, McKemey was a particle physicist, a tenured faculty member at Brunel University in London and a visiting professor at Stanford University, where he consulted to pharmaceutical and diagnostic companies on commercializing his research.

Jim Featherstone, Ph.D., Practice Leader, Regulatory and Quality and Product Development and Commercialization, Europe - Featherstone will grow the Product Development and Commercialization practice in Europe, as well as oversee and expand the existing regulatory and quality consulting services in Europe.

Featherstone joins Quintiles from Wood Mackenzie, a leading business intelligence and strategy consulting services company based in the U.K., where he was the Global Head of Consulting for the Pharmaceuticals and Biotechnology practice. Featherstone joined Wood Mackenzie in 2000 to build the life sciences strategic consulting practice, defining the overall strategy and executing growth in the European and U.S. markets. Prior to this, Featherstone was with the pharmaceutical division of British Petroleum, which he joined after a distinguished academic career.

Matt Eberhart, MBA, Vice President, Business Development - Eberhart is responsible for establishing a global business development framework, leading the business development efforts in the U.S. and serving as the internal liaison to the broader Quintiles organization.

Eberhart has worked with a number of emerging professional services companies in the life sciences industry, building and managing sales and marketing organizations. Previously, Eberhart was an executive management team member at Katalyst, a privately held venture capital and advisory firm. He has also served as a Senior Manager and European Leadership Team member for Deloitte Consulting's Life Sciences Practice.

"Each new member of the team brings strong consulting practice-building skills, entrepreneurial capabilities and deep life sciences industry knowledge," said Jay Norman, President of Quintiles Consulting. "Quintiles is well positioned to become the premier global provider of strategic consulting to the life sciences industry."

About Quintiles Consulting

Quintiles Consulting works with pharmaceutical, biotech and medical device companies to maximize potential and minimize risk from discovery through development and commercialization by providing expert strategic, operational and technical advice. Building on the global reach and expertise of Quintiles Transnational, Quintiles Consulting practice areas include Product Development and Commercialization, Regulatory and Quality, and Market Access. Quintiles Consulting has full-time consultants based across the U.S. and Europe to serve its global clients. For more information, please visit http://www.quintiles.com/consulting .

About Quintiles

Quintiles Transnational Corp. is powering the next generation of healthcare by providing a broad range of professional services in drug development, financial partnering and commercialization for the biotechnology and healthcare industries. With more than 20,000 employees and offices in more than 50 countries, it is focused on providing customer-centric solutions that are the gold standard of the industry. For more information, please visit the company's Web site at http://www.qtrn.com .


'/>"/>
SOURCE Quintiles Transnational Corp.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Quintiles Completes Previously Announced New Investor Partnership, Co-Led by Founder, Chairman and CEO Dennis Gillings, Bain Capital, TPG and 3i
2. Quintiles to Open Clinical Research Office in Wilmington, NC
3. Quintiles Central Lab, Clinical Development in China to Expand, Relocate to New Facility
4. Quintiles Names Kelly McKee Executive Director of Operations for Public Health and Government Services Unit
5. Expert Cardiologist Joins Quintiles Medical Group
6. Michael Troullis Appointed Chief Financial Officer of Quintiles Transnational Corp.
7. Tunnell Consulting Expands Biotechnology Expertise
8. Cinpathogen Provides Clinical Diagnostic Consulting Services to Shanghai Area Hospitals
9. Parexel Consulting Strengthens Good Manufacturing Practice Capabilities in Europe
10. Pharsight Expands Strategic Consulting Services Team
11. Pathology Consultants, Inc. Selects PSA, LLC, a MED3OOO Company, as Their Business Partner
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... DIEGO , March 27, 2017  Trovagene, Inc. ... that its Chief Executive Officer, Bill Welch , ... April 4, 2017 at 9:00 AM EDT at the ... .  Bill Welch, and Chief Scientific Officer, Mark ... with investors during the conference.   The presentation ...
(Date:3/24/2017)... Research and Markets has announced the addition of the "Human ... report to their offering. ... This report analyzes the Global market for Human Embryonic ... are provided for the period 2014 through 2022. Market data and ... The report profiles 25 companies including many key and niche players ...
(Date:3/23/2017)... ... 2017 , ... AxioMed president, Jake Lubinski, describes the AxioMed ... deformed, which is identical to how the human discs work to distribute force. ... to its natural state along a hysteresis curve, exactly like a healthy human ...
(Date:3/23/2017)... 2017  GlobeImmune, Inc. today announced it has entered ... 12,835,490 shares of its common stock to NantCell, Inc., ... with the sale of its common stock, NantCell has ... to GlobeImmune 200,000 shares, an estimated $2.0 million in ... are pleased to enter into this strategic agreement with ...
Breaking Biology Technology:
(Date:3/27/2017)... , March 27, 2017  Catholic Health ... and Management Systems Society (HIMSS) Analytics for achieving ... Adoption Model sm . In addition, CHS previously ... U.S. hospitals using an electronic medical record (EMR). ... its high level of EMR usage in an ...
(Date:3/24/2017)... , March 24, 2017 The Controller General ... Controller Mr. Abdulla Algeen have received the prestigious international IAIR ... Continue Reading ... ... picture) and Deputy Controller Abdulla Algeen (small picture on the right) have ...
(Date:3/24/2017)... Mar 24, 2017 Research and Markets has ... Market Analysis & Trends - Industry Forecast to 2025" report ... ... at a CAGR of around 15.1% over the next decade to ... report analyzes the market estimates and forecasts for all the given ...
Breaking Biology News(10 mins):